Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.
Melanoma|Cancer
DRUG: Encorafenib + Binimetinib|DRUG: Standard Adjuvant Treatment
Pathological response rate, % of patients with a complete response using Haemotoxylin and Eosin staining of tumour removed at surgery., During scheduled surgery
Treatment compliance, Incidence of missed treatment doses assessed from number of tablets returned., Through study completion for an average of 12 months|Radiological response, % of patients with a complete response using CT scan tumour measurement assessment (RECIST) from start of treatment until 8 weeks., Through study completion for an average of 12 months|Toxicity of treatment, Rate of patients with drug related toxicities reported from start of study until end of treatment, Through study completion for an average of 12 months|Lymphoedema toxicity, Incidence of lymphoedema toxicity using circumferential limb measurement and questionnaires for an average of 12 months., Through study completion for an average of 12 months|Survival rate, Number of patients deceased from start of treatment for an average of 12 months., Through study completion for an average of 12 months|Quality of life, Quality of life assessed by Functional Assessment of Cancer Therapy - Melanoma (FACT-M) questionnaire for an average of 12 months., Through study completion for an average of 12 months|Recruitment rate, Rate of monthly recruitment achieved during the last 6 months of the trial recruitment period, Through study completion for an average of 12 months
A phase II, multi-centre, open label, randomised trial.

The trial will assess the delivery, response rate, treatment compliance, efficacy and safety of encorafenib and binimetinib compared to standard adjuvant therapy in patients with BRAFV600 mutant clinically detected AJCC stage III(B/C/D) or oligometastatic stage IV Melanoma.